Search
Safety profile and adverse event management for futibatinib, an irreversible FGFR1–4 inhibitor: pooled safety analysis of 469 patients
Meric-Bernstam F, Hollebecque A, Furuse J, et al. Clinical Cancer Research. 2024; 30 (8): 1466–1477
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer
Goyal L, Meric-Bernstam F, Hollebecque A, et al. Future Oncology. 2024:1-12.
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
Goyal L, Meric-Bernstam F, Hollebecque A, et al. New England Journal of Medicine. 2023;388(3):228-239.
Discovery of futibatinib: the first covalent FGFR kinase inhibitor in clinical use
Ito S, Otsuki S, Ohsawa H, et al. ACS Medicinal Chemistry Letters. 2023;14(4):396-404.
A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
Gao L, Yamamiya I, Pinti M, et al. Clinical and translational science. 2023;16(9):1713-1724.
Evaluation of the cytochrome P450 3A and p-glycoprotein drug-drug interaction potential of futibatinib
Yamamiya I, Hunt A, Takenaka T, et al. Clinical Pharmacology in Drug Development. 2023;12(10):966-978.
Evaluation of the mass balance and metabolic profile of futibatinib in healthy participants
Yamamiya I, Hunt A, Yamashita F, et al. Clinical pharmacology in drug development. 2023;12(9):927-939.
Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib
Yamamiya I, Hunt A, Yamashita F, et al. Clinical Pharmacology in Drug Development. 2023;12(3):294-303.
Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, QT/QTc, phase 1 study in healthy subjects
Yamamiya I, Lester R, Sonnichsen D, et al. Clinical Pharmacology in Drug Development. 2022;12(3):304-313.
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Meric-Bernstam F, Bahleda R, Hierro C, et al. Cancer Discovery. 2021;12(2):402-415.
Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors
Sootome H, Fujita H, Ito K, et al. Cancer Research. 2020;80(22):4986-4997.
Phase I, first-in-human study of futibatinib, a highly Selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Bahleda R, Meric-Bernstam F, Goyal L, et al. Annals of Oncology. 2020;31(10):1405-1412.